EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population

Detalles Bibliográficos
Autores principales: Sutton, K, Miller, P, Branscombe, N, Mittal, M, Browne, C, Arnetorp, S, Henry, T, Breslin, K, Bungey, G, Quint, J, Montgomery, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747408/
http://dx.doi.org/10.1016/j.jval.2022.09.812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747408/
http://dx.doi.org/10.1016/j.jval.2022.09.812

Ejemplares similares